Key result
The CHA2DS2-VASc score effectively identifies truly low-risk atrial fibrillation patients who do not require anticoagulation and predicts thromboembolic events after catheter ablation.
The CHA2DS2-VASc score effectively identifies truly low-risk AF patients who do not require anticoagulation and predicts thromboembolic events post-catheter ablation.
The incidence of atrial fibrillation (AF) was around 1.5 per 1000 person-years in Taiwan. Systemic thromboembolism is the most severe complication of AF. Risk stratification and adequate thromboembolism prophylaxis is the cornerstone of treatment in AF patients. The CHA2DS2-VASc score is powerful in selecting "truly low-risk" patients who are not necessary to receive anticoagulation therapies. It is also useful in predicting thromboembolic events and mortality for patients undergoing AF ablation. Recently, more and more biomarkers and imaging parameters were reported to be associated with adverse events in AF patients. How could these biomarkers and imaging tools change the current strategy of stroke prevention in AF deserves further investigations.
No takes yet. Share an insight, caveat, or question.
Chao et al. (2013) conducted a review in Atrial Fibrillation. Stroke prevention strategies (CHA2DS2-VASc score, catheter ablation) was evaluated. The CHA2DS2-VASc score effectively identifies truly low-risk atrial fibrillation patients who do not require anticoagulation and predicts thromboembolic events after catheter ablation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: